Neurocrine Biosciences Inc vs Northern Trust Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $136.35 (market cap $13.82B), while Northern Trust Corporation Common Stock trades at $162.48 (market cap $29.76B). The key difference: Northern Trust Corporation Common Stock is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Northern Trust Corporation Common Stock pays a 2.02% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 24 Days and Northern Trust Corporation Common Stock for 0 Days on average.
| NBIX | NTRS | |
|---|---|---|
Market Cap | $13.82B | $29.76B |
Volume | 1,506,669 | 1,427,762 |
Sector | Health | Financials |
52-Week High | $185.50 | $191.47 |
52-Week Low | $123.10 | $122.72 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $13.83B | -$6.24B |
Dividend Yield | — | 2.02% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 19.87 and robust profitability, including a net income margin of 20.91% and three consecutive quarterly earnings beats. Recent news highlights pipeline progress and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive given strong earnings momentum and product growth, but risks include execution challenges and pricing pressures. The current price offers a significant discount to the analyst target, presenting a potential opportunity for investors comfortable with the biopharmaceutical sector's inherent volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →